Evidence map›Paper›PMID 36338146›Full record

ArticleOncoimmunology2022

Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis.

Alfonso Serrano Del Valle, Manuel Beltrán-Visiedo, Victoria de Poo-Rodríguez, Nelia Jiménez-Alduán, Gemma Azaceta, Rosana Díez, Beatriz Martínez-Lázaro, Isabel Izquierdo, Luis Palomera, Javier Naval and 2 more

Open access · goldAbstract read
In one paragraph

Article in Oncoimmunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Alfonso Serrano Del ValleApoptosis, Immunity & Cancer Group, IIS Aragón, University of Zaragoza, 50009 Zaragoza, Spain.ORCID 0000-0001-9343-1050
Manuel Beltrán-VisiedoApoptosis, Immunity & Cancer Group, IIS Aragón, University of Zaragoza, 50009 Zaragoza, Spain.ORCID 0000-0002-7977-8020
Victoria de Poo-RodríguezHematology Service, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain.ORCID 0000-0002-0955-9949
Nelia Jiménez-AlduánApoptosis, Immunity & Cancer Group, IIS Aragón, University of Zaragoza, 50009 Zaragoza, Spain.
Gemma AzacetaHematology Service, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain.ORCID 0000-0001-5068-7355
Rosana DíezApoptosis, Immunity & Cancer Group, IIS Aragón, University of Zaragoza, 50009 Zaragoza, Spain.
Beatriz Martínez-LázaroHematology Service, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain.
Isabel IzquierdoApoptosis, Immunity & Cancer Group, IIS Aragón, University of Zaragoza, 50009 Zaragoza, Spain.
Luis PalomeraHematology Service, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain.ORCID 0000-0001-8515-3599
Javier NavalApoptosis, Immunity & Cancer Group, IIS Aragón, University of Zaragoza, 50009 Zaragoza, Spain.ORCID 0000-0003-2156-8378
Alberto AnelApoptosis, Immunity & Cancer Group, IIS Aragón, University of Zaragoza, 50009 Zaragoza, Spain.
Isabel MarzoApoptosis, Immunity & Cancer Group, IIS Aragón, University of Zaragoza, 50009 Zaragoza, Spain.ORCID 0000-0002-2315-9079
Universidad de Zaragoza · ESHospital Clínico Universitario Lozano Blesa · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunogenic cell death (ICD) has been proposed to be a crucial process for antitumor immunosurveillance. ICD is characterized by the exposure and emission of Damage Associated Molecular Patterns (DAMP), including calreticulin (CRT). A positive correlation between CRT exposure or total expression and improved anticancer immunosurveillance has been found in certain cancers, usually accompanied by favorable patient prognosis. In the present study, we sought to evaluate CRT levels in the plasma membrane of CD38

Indexed as

CalreticulinMultiple MyelomaAlarminsHumansImmunityPrognosisTumor MicroenvironmentAlarminsCalreticulinCalreticulinimmunogenic cell deathmultiple myeloma

Identifiers

PMID36338146
PMCPMC9629093
OpenAlexW4307831347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.